Levofloxacin versus betalactamic therapy in community-acquired pneumonia that requires hospitalization;Levofloxacino frente a betalactámicos en el tratamiento de la neumonía adquirida en la comunidad con ingreso hospitalario

Anales de Medicina Interna

Volumn 19, Issue 12, 2002, Pages 621-625

  Geijo Martinez Ma P ^a,b   Diaz De Tuesta Chow Quan A M ^a   Rosa Herranz, C ^a   Gomez Criado C ^a   Dimas Nunez J F ^a   Saiz Garcia F ^a  

^a Hospital General   (Spain)

^b Hospital de Cuenca   (Spain)

Author keywords

Antibiotic treatment; Community acquired pneumonia; Levofloxacin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CLARITHROMYCIN; LEVOFLOXACIN; MACROLIDE;

ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; COLITIS; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG PREFERENCE; FEMALE; GENDER; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; INFECTION COMPLICATION; LENGTH OF STAY; MALE; PNEUMONIA; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEPSIS; SPAIN; STATISTICAL SIGNIFICANCE;

EID: 18844463499     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Dorca J. Fernández S. Tratamiento de la neumonía comunitaria. Arch Bronconeumol 1998; 34 (Supl. 2): 50-56.
2. Kalbermatter V, Bagilet D, Diab M, Javkin E. Levofloxacino oral versus ceftriaxona y amoxicilina/ácido clavulánico en el tratamiento de la neumonía adquirida en la comunidad con criterio de ingreso. Med Clin (Barc) 2000; 4; 115 (15): 561-3.
3. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J; CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001; 119(1): 185-95.
4. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH and the Canadian Community-Adquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383-421.
5. Weinstein RA. Practice guidelines make perfect, Part II: Community-acquired pneumonia in adults. 38th Annual Meeting of the Infectious Diseases Society of America. Infectious Disease Conference Summaries 2000. Medscape.
6. Bayas JM, Vilella A, San-Martín M, González A, Conesa A, Asenjo MA. Impacto sanitario de los ingresos por neumonía en un hospital del tercer nivel. Med Clin (Barc) 2001; 116: 694-5.
7. Álvarez Sanchez B, Álvarez-Lerma F, Jordá R, Serra J, López-Cambra MJ, Sandar MD, y Grupo de estudio de neumonía comunitaria grave en España. Factores pronósticos y etiología de los pacientes con neumonía grave ingresados en UCI. Med Clin (Barc)1998; 111: 650-54.
8. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine M J, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
9. Theenhakarai R, El-Halees W, Ismail M, Solis R A, Khan MA. Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Chest 2001; 119: 181-4.
10. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with Community-acquired Pneumonia. N Engl J Med 1997; 336: 243-50.
11. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA et al Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-141.
12. Medrano González F, Solis García del Pozo J, Gomariz García S y Solera Santos J. Neumonia adquirida en la comunidad que requiere ingreso hospitalario. Una comparación del manejo clínico, consumo de recursos y pronóstico entre diferentes especialidades médicas. Rev Clin Esp 2001; 201: 65-68.
13. Grupo de Estudio de la Neumonia Adquirida en la Comunidad Tratada Ambulatoriamente (NACTA). Diagnóstico y tratamiento de pacientes con neumonía adquirida en la comunidad: variabilidad de las pruebas complementarias y estudio de la efectividad de roxitromicina. Rev Clin Esp 1999; 199(11): 700-704.
14. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, et al. Guideliness for the management of adults with Community-adquired pneumonia. American Thoracic Society. Am J Respir Crit Care Med 2001; 163: 1730-45.
15. Álvarez-Sala JL, Serrano R. Neumonía en el anciano. Med Clin (Barc) 2001; 117: 454-456.
16. Álvarez Gutiérrez FJ, García Fernández A, Elías Hernández T, Romero Contreras J, Romero Romero B, Castillo Gómez J. Neumonías adquiridas en la comunidad en pacientes mayores de 60 años. Incidencia de gérmenes atípicos y evolución clinicorradiológica. Med Clín (Barc) 2001; 117: 441-445.
17. Bartlett JG, Dowell SF, Mandell LA, File TM, Jr, Musher DM, Fine MJ. Practice guidelines for the management of community- adquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82.
18. Hoeffken G, Meyer HP, Winter J, Verhoef L; CAP1 Study Group. The eficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001; 95(7): 553-64.
19. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-39.
20. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917-1924.
21. Daily P, Gelling L, Rothrock G, Reingold A, Vugia D, Barrett NL, Hadler J, Baughman W, Farley M, Blake PA, Pas MA, Roche J. et al. Resistance of Streptococcus Pneumoniae to Fluoroquinolones-United States, 1995-1999. Centers for Disease Control 2001.MMWR 50(37): 800-804.
22. Mirete Ferrer C, Gutierrez Rodero F, Rodríguez Díaz JC, Royo García G, Shum Fhunk C y Martín Hidalgo A. Etiología de la neumonia adquirida en la comunidad tratada ambulatoriamente. Utilidad de un protocolo diagnóstico con pruebas microbiológicas convencionales y detección de antígenos de Streptococcus pneumoniae y Legionella pneumophila en orina. Med Clin (Barc) 2001; 117: 657-659.
23. Liñares J, de la Campa AG, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999; 341: 1546-48.
24. Rittenhouse BE, Stinnett AA, Dulisse B, Henke CJ, Potter L, Parasuraman B, Martens LL, Williams RR, Kojak C. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia. Am J Manag Care 2000; 6(3): 381-9.